A Comparative Clinical Study to Evaluate the Efficacy of Jalaukavacharana and Jalaukavacharana with Manjishthadi Aditya Pak Taila in the Management of Pama w.s.r. to Eczema. - NIL

Start Date10 Jun 2026

Sponsor / Collaborator-

ChiCTR2500100084

/ Not yet recruitingEarly Phase 1IIT

Mechanism of mannose promoting cholesterol excretion

Start Date07 Apr 2025

Sponsor / Collaborator-

NCT06507735

/ CompletedNot ApplicableIIT

The Effects of Mannose Supplementation on Glycosylation and Protein Levels in Human Sera

The purpose of our study is to investigate the effects of supplemental mannose on sera of humans who are healthy. We will perform proteomics studies to elucidate changes to glycan structure and protein level changes. We hypothesize that we may find that mannose supplies more properly glycosylated protein substrate and helps expedite protein synthesis, that excess mannose leads to alternative glycan structures which confer improved stability, or that there are new sites that become glycosylated after mannose supplementation.

Start Date29 Oct 2024

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Mannose

100 Translational Medicine associated with Mannose

100 Patents (Medical) associated with Mannose

26,866

Literatures (Medical) associated with Mannose

01 Sep 2026·Molecular Genetics and Metabolism Reports

Management of pregnancy and outcomes in a woman with mannose-6-phosphate isomerase deficiency (MPI-CDG)

Article

Author: Woodall, Alison ; Mighell, Amal ; Khin, May Oo ; Sia, Priscilla ; Hussain, Afifah ; Moreea, Sulleman ; Bassett, John ; Hufton, Amy ; Jowett, Sarah ; Loh, Jia Hui Megan ; Stepien, Karolina M

Congenital Disorder of Glycosylation type Ib (MPI-CDG) is a rare autosomal recessive metabolic disorder caused by deficiency of mannose-6-phosphate isomerase, resulting in impaired N-glycosylation. Unlike other CDG subtypes, MPI-CDG is not associated with neurodevelopmental impairment and is effectively treated with oral D-mannose supplementation. However, evidence guiding management during pregnancy is scarce, and D-mannose is generally avoided due to limited safety data. We describe the long-term course and pregnancy outcomes of a woman diagnosed with MPI-CDG in infancy. She was treated with oral D-mannose throughout childhood with good clinical response but demonstrated intermittent non-compliance in adulthood, complicated by hepatic fibrosis, protein-losing enteropathy, osteoporosis, anaemia, and musculoskeletal manifestations. She had two pregnancies without D-mannose supplementation. The first pregnancy was complicated by microcytic anaemia, hypoalbuminemia, pregnancy-induced cholestasis, and emergency caesarean section. A male infant was delivered and later diagnosed with Hirschsprung disease, requiring surgical correction with good outcome. Postpartum assessment of the mother demonstrated progression of liver disease to cirrhosis (F4). The second pregnancy proceeded with fewer complications and resulted in emergency caesarean delivery of a healthy female infant with normal postnatal glucose control and growth. This case contributes to the limited literature on pregnancy in MPI-CDG and illustrates that successful pregnancies are possible despite advanced multisystem disease and cessation of D-mannose therapy. It highlights the importance of multidisciplinary care, close hepatic and nutritional monitoring, and the need for further studies to clarify the safety and role of D-mannose supplementation during pregnancy.

01 Sep 2026·CURRENT DIABETES REVIEWS

Metabolomics-Based Study: Effects of Fructose, Glucose, and Mannose on Islet Cells and Change of Serum Markers in Streptozotocin-Induced Diabetic Rats

Article

Author: Zhang, Lijun ; Chen, Fangfang ; Guo, Shuang ; Gu, Jianxing ; Li, Xueyan ; Fan, Yuan ; Liu, Tao ; Tang, Zhusheng ; Long, Xiaomei ; Li, Rong

Introduction::

experiment uses metabolomics to explore the effects of glucose, fructose, and mannose on the metabolism and pancreatic islet structure of rats, providing ideas and references for clinical and practical applications.

Method::

In this experiment, rats were randomly divided into four groups of 10 rats each: the normal control group, glucose group, fructose group, and mannose group. The sugar for each group was dissolved in water and freely ingested by the rats for 8 weeks. After 8 weeks, 5 rats were randomly selected from each group and injected intraperitoneally with STZ. After three days of observation, tissues were collected. Pathological tissue staining was performed to analyze the structure of rat pancreatic islets, and metabolomics analysis was conducted on rat serum. Based on the differential metabolites, predictive analysis of the metabolic pathways of the three monosaccharides was performed.

Result::

The results showed that glucose had a protective effect on rat pancreatic islet structure and reduced the degree of islet destruction caused by STZ. Fructose had a weaker protective effect than glucose but still demonstrated some protection. Mannose showed almost no protective effect on rat pancreatic islet function.

Discussion::

Serum metabolomics analysis suggested that the possible mechanisms underlying the effects of different monosaccharides on rats involved tyrosine metabolism, pentose phosphate metabolism, and Type 2 diabetes mellitus. In contrast, the potential mechanisms associated with STZ injection were related to arginine and proline metabolism, the mTOR signaling pathway, and amoebiasis.

Conclusion::

This experiment systematically revealed the differential effects of glucose, fructose, and mannose on the structural protection and metabolic pathways of rat pancreatic islets through metabolomics and histopathological analyses, providing an important theoretical basis for diabetic nutritional intervention and drug target development.

01 Jun 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

Engineered -derived exosome-like nanoparticles as a dual-targeting platform for eradicating intracellular methicillin-resistant

Article

Author: Challa, Mahesh ; Zhang, Ruixue ; He, Yun ; Qiu, Yanfei ; Deng, Xinyue ; Gong, Zhi ; Huang, Chao ; Shi, Gongming ; Yang, Xiaohong

Intracellular infections caused by methicillin-resistant Staphylococcus aureus (MRSA) present a significant therapeutic challenge due to the limited access of conventional antibiotics to bacterial reservoirs within macrophages. To address this, we developed a dual-targeting delivery system using Houttuynia cordata-derived exosome-like nanoparticles (HELNs) functionalized with mannose and vancomycin for rifampicin (Rif) encapsulation (Rif@HELNs-MV). The engineered nanoparticles were designed to sequentially target macrophages through mannose receptor-mediated endocytosis and subsequently bind to intracellular MRSA via vancomycin-peptidoglycan interactions. Systematic characterization revealed that Rif@HELNs-MV maintained structural integrity with a spherical morphology, high Rif loading capacity (18.3 ± 2.1 %). Cellular assays demonstrated enhanced uptake and precise targeting to intracellular MRSA. The formulation showed superior antibacterial efficacy in murine models of peritonitis and muscle infection, significantly reducing bacterial loads while exhibiting excellent biocompatibility. This dual-targeting strategy represents a promising approach for treating persistent intracellular infections by overcoming the physiological barriers that limit conventional antibiotic therapies.

News (Medical) associated with Mannose

28 Apr 2026

·www.prnewswire.com

Cadence OTC Launches First-of-Its-Kind UTI Emergency Relief Kit at Walmart Stores

The new product pairs OTC medications with a novel drink mix supplement to deliver science-backed ingredients to store aisles nationwide OAKLAND, Calif., April 28, 2026 /PRNewswire/ -- Cadence OTC, a Public Benefits Company redefining access to reproductive healthcare including emergency contraception, today announced the launch of its UTI Emergency Relief Kit. It is the first product of its kind to package two over-the-counter (OTC) medications side-by-side with a targeted proprietary drink mix supplement. The new kit is formulated with clinically-studied components that promote urinary tract health and comfort, particularly when used early at the very first signs. Continue Reading Cadence OTC "UTIs can sometimes be stopped if addressed within the first few hours of symptoms," said Dr. Nap Hosang, OBGYN, Chief Medical Officer and Co-Founder of Cadence OTC. "Oftentimes while patients wait for a doctor's appointment, the critical prevention window closes, allowing the infection to progress, causing extensive suffering and requiring antibiotics. Acting fast at the very first symptom of an emerging UTI can mean the difference between stopping an infection and fighting one." UTIs affect more than 15 million women annually, with a quarter experiencing recurrent infections multiple times a year. Despite driving $2 billion in annual healthcare spending, over-the-counter UTI treatment to-date has required women to find and assemble various separate products and ingredients. There is also a gap in education around the OTC infection control medicine, methenamine, which only activates when urine is acidic. To solve this, the Cadence UTI Emergency Relief Kit introduces pH Power Flush, a proprietary acidifying drink mix that contains vitamin C ascorbic acid, cranberry proanthocyanidins (PACs), and D-mannose, making the kit an overall OTC solution for use during the urgent window when a UTI infection is first trying to take hold. Early interventions can work synergistically to help your body prevent infection if used quickly at the very first signs: water mechanically flushes out loose bacteria; D-mannose acts as a decoy that bacteria grab instead of bladder walls; cranberry PACs block bacterial adhesion; methenamine converts to an antibacterial agent in acidic urine. The UTI Emergency Relief Kit is packaged for convenience and not intended to replace medical care. If symptoms persist, a QR code included inside the kit links directly to Cadence's telemedicine partner, TwentyEight Health, to quickly access care and send an antibiotic prescription to any pharmacy in four to six hours. No other kit combines a supplement with OTC medications for UTI relief. The complete four-in-one regimen is priced under $30 and each kit includes: Two test strips 12 phenazopyridine HCl tablets for urinary pain relief 12 methenamine tablets for infection control Four pH Power Flush packets containing 1,500mg ascorbic acid (Vitamin C), whole cranberries equivalent to 36mg proanthocyanidins (PACs), and 2,000mg D-mannose * The statements about the dietary supplement bundled in the Cadence UTI Kit have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. At launch, the UTI Emergency Relief Kit is an exclusive retail launch at Walmart. Cadence additionally plans to expand distribution into convenience stores, quick commerce and college campus delivery services like Snag, to ensure the most comprehensive kit on the market is also the most affordable and available in nearly every zip code in America. "At Cadence, we don't just sell products; we aim to solve the systemic gaps in women's healthcare. As a Public Benefit Company, we have the unique mandate to make major investments in improving health outcomes that traditional corporations often overlook," said Samantha Miller, CEO and Co-Founder of Cadence OTC. "The UTI Relief Kit is the next step in our mission to provide women with the medical care they deserve, exactly when and where they need it. Our strategic partnerships with leading retail, convenience, and delivery locations are a direct reflection of that commitment." This launch is the latest milestone in Cadence OTC's mission to close healthcare gaps by moving essential care products into more than 18,000 retail locations, including pharmacy deserts. Beyond UTI relief, the company is a leader in reproductive health, offering an affordable Morning After PillⓇ and an industry-leading "No Expiration Guarantee" that provides free replacements for expired Cadence OTC products to encourage proactive purchases. Cadence is also currently pioneering the Rx-to-OTC switch of the most commonly used daily birth control pill – to make it available without a prescription, redefining reproductive autonomy for women everywhere. For more information about Cadence OTC, the UTI Relief Kit, and its mission to increase access to emergency contraceptives, please visit cadenceotc.com. About Cadence OTC: Cadence OTC is a Public Benefits consumer healthcare company based in Oakland, CA, on a mission to increase over-the-counter (OTC) access to safe, effective, affordable contraceptives for everyone everywhere. Cadence holds rights to three of the most popular oral contraceptive formulations and is in the process of moving Zena, their combined birth control pill, from prescription to over-the-counter. We are also, for the first time ever, bringing an OTC emergency contraceptive to convenience stores nationwide. The company is founded and led by renowned reproductive health experts, experienced healthcare entrepreneurs, and supporters who care deeply about making birth control equally accessible and safe for all people. Media Contact: [email protected] SOURCE Cadence OTC 21% more press release views with Request a Demo

29 Jan 2025

·www.businesswire.com

D-Mannose Industry Research Report 2024-2030: Demand for Organic and Non-GMO Supplements, & Expansion of Clinical Studies Supporting Growth - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "D-Mannose - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for D-Mannose was estimated at US$830.8 Million in 2023 and is projected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growing awareness of the benefits of natural and non-prescription treatments has contributed to the popularity of D-Mannose among health-conscious consumers. It is frequently recommended as a preventive solution, especially for individuals with recurrent UTIs. With an increasing preference for natural and functional health products, D-Mannose is becoming a staple in the dietary supplement market. What Factors Are Driving the Growth of the D-Mannose Market? The growth in the D-Mannose market is driven by several factors, including the increasing preference for natural health products, rising consumer awareness about urinary health, and scientific research validating its benefits. The trend towards self-care and preventive health management has led consumers to seek non-pharmaceutical alternatives, boosting D-Mannose sales as a trusted and effective option. The rise of e-commerce platforms has further facilitated access to these products, making them available to a global audience. In addition, the focus on women's health and the emphasis on solutions for recurrent UTIs have propelled the demand for D-Mannose. Innovation in product formulations, such as incorporating D-Mannose with probiotics or other natural ingredients, also contributes to market growth by appealing to health-conscious consumers seeking holistic and multifunctional supplements. How Are Scientific Studies Supporting the Growth of the D-Mannose Market? The scientific validation of D-Mannose's efficacy in preventing UTIs has played a significant role in the expansion of its market. Clinical studies have demonstrated that D-Mannose can significantly reduce the incidence of recurrent UTIs without the adverse effects associated with long-term antibiotic use. These findings have led healthcare professionals and naturopaths to recommend D-Mannose as a preventive measure or supplementary treatment for urinary health. Furthermore, research exploring its additional benefits, such as improving gut health and supporting overall immune function, is expanding its application scope beyond urinary care. This scientific backing not only boosts consumer confidence but also attracts investment and innovation in the development of D-Mannose products, including powders, capsules, and beverages. Where Are D-Mannose Products Being Utilized and Sold? D-Mannose products are primarily sold through health stores, pharmacies, and online retail platforms specializing in dietary supplements. The convenience of e-commerce has allowed consumers to access D-Mannose products easily, contributing to its widespread availability and use. Apart from standalone supplements, D-Mannose is also incorporated into combination products that address urinary health, such as cranberry supplements and probiotics. This multifunctional approach appeals to consumers seeking comprehensive wellness solutions. Additionally, healthcare professionals and clinics focusing on natural medicine and women's health often recommend and distribute D-Mannose, increasing its penetration into medical and wellness practices. The growth in demand is not limited to developed markets; emerging economies are also witnessing increased adoption as awareness of natural and preventive healthcare options rises. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players in the Global D-Mannose Market such as Atrium Innovations, Inc., Biotech Pharmacal, Inc., Dow, Inc., DuPont de Nemours, Inc., Hanseler AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the D-Mannose Capsule segment, which is expected to reach US$592.9 Million by 2030 with a CAGR of a 4.1%. The D-Mannose Tablet segment is also set to grow at 3.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $223.7 Million in 2023, and China, forecasted to grow at an impressive 5.9% CAGR to reach $218.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Attributes: Report Attribute Details No. of Pages 246 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $830.8 Million Forecasted Market Value (USD) by 2030 $1100 Million Compound Annual Growth Rate 3.7% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of COVID-19 and a Looming Global Recession D-Mannose - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Prevalence of Urinary Tract Infections (UTIs) Boosting Demand for D-Mannose Growing Consumer Preference for Natural and Plant-Based Supplements Increasing Awareness About the Health Benefits of D-Mannose in Preventive Healthcare Development of D-Mannose-Based Products for Enhanced Bioavailability Expansion of the Functional Foods and Dietary Supplements Market Supporting Growth Increasing Focus on Women's Health and UTI Prevention Driving Product Adoption Rising Popularity of D-Mannose as an Alternative to Antibiotics Growth in Online Retail Channels Expanding Accessibility of D-Mannose Supplements Demand for Organic and Non-GMO Supplements Fueling Market Expansion Expansion of Clinical Studies Validating the Efficacy of D-Mannose in UTI Treatment Innovations in Product Formulations Such as Capsules, Powders, and Gummies Increase in Direct-to-Consumer Marketing Strategies Expanding Market Reach FOCUS ON SELECT PLAYERS: Some of the 46 companies featured in this Global D-Mannose report include Atrium Innovations, Inc. Biotech Pharmacal, Inc. Dow, Inc. DuPont de Nemours, Inc. Hanseler AG Jarrow Formulas, Inc. Kyowa Hakko Kirin Co., Ltd. Now Health Group, Inc. Nutraceutical Corporation Pfanstiehl, Inc. VWR International LLC For more information about this report visit https://www.researchandmarkets.com/r/8v07au About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

28 Mar 2024

·www.fiercebiotech.com

Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug

Avalo only has eyes for the drug and won’t be taking on any of Almata’s staff. Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa (HS). The anti-IL-1β mAb, dubbed AVTX-009, has its origins at Eli Lilly. Avalo CEO Garry Neil, M.D., said the antibody has a “high probability of success for the treatment of HS as evidenced by recent data readouts validating inhibition of IL-1β in this disease.” “We believe that HS is a multi-billion-dollar commercial opportunity and that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing,” Neil added in a post-market release yesterday. Avalo will make AVTX-009 its lead asset, ahead of quisovalimab, an anti-LIGHT mAb in phase 2 development for ulcerative colitis, and AVTX-008, a BTLA agonist fusion protein in preclinical development. The biotech expects to read out topline results from a phase 2 study of AVTX-009 in HS in 2026, and also alluded to plans to evaluate the antibody in another chronic inflammatory indication. To get its hands on the drug, Avalo is paying out $15 million in stock and a further $7.5 million in cash to acquire Almata outright. Almata’s former stockholders are also in line for a $5 million payout when the first patient is dosed in the phase 2 trial and $15 million if a patient is dosed in a phase 3 trial. The acquisition of privately-held Almata marks the end of a short life for the biotech, which was set up in April 2023 with the aim of identifying and licensing AVTX-009. While Almata will become a subsidiary of Avalo, the new owner only has eyes for the drug itself and won’t be taking on any of Almata’s staff. "We are pleased that Avalo recognizes the promise of AVTX-009, an important potential treatment option for patients with inflammatory diseases,” Almata’s now-former CEO Patrick Crutcher said in the release. “AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio team to this mission,” Crutcher added. “We look forward to the advancement of AVTX-009 into a phase 2 trial in HS under Dr. Neil’s stewardship.” Avalo hasn’t had an easy time in recent years. Back in 2022, the company was forced to cut down its pipeline and lost a chunk of its C-suite. Only last summer, the biotech had to work through a default with creditors before selling off its rare disease meds AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics. But with $35 million in debt eliminated and potentially up to $45 million in milestone payments to come from the offloaded AVTX-800 series, Avalo ended 2023 in a better place, even if it only had $10 million in the bank. Luckily, Avalo’s money worries have now been eased, with the company also announcing yesterday a $185 million raise via a private placement of various types of stock. The funding is expected to fuel the phase 2 trial of AVTX-009 and beyond into 2027. Investors appeared relieved at Avalo’s change in fortunes, sending the biotech’s stock rocketing over 330% in pre-marketing trading this morning to $20.50 from a Wednesday closing price of $4.75.

Phase 2AcquisitionPhase 3Phase 1

100 Deals associated with Mannose

External Link

KEGG	Wiki	ATC	Drug Bank
D12572	Mannose	-	DB12907

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Tract Infections	Phase 3	Italy	-	01 Jan 2012
Multiple Sclerosis	Phase 1	United Kingdom	University College London	01 Feb 2015
Bladder Cancer	Preclinical	China	The First Affiliated Hospital of Guangzhou Medical University	01 May 2025
Bladder Cancer	Preclinical	China	Dalian University of Technology	01 May 2025
Congenital Disorder of Glycosylation Type 1B	Preclinical	United States	Avalo Therapeutics, Inc.	01 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISRCTN13283516 (Pubmed \| JAMA Intern Med)	Phase 3	Urinary Tract Infections	598	d-Mannose	zkcjkcglea(mwbyfvhdlr) = dxgpfyuewa rdwaeteolh (hezrvuklle )	Negative	01 Jun 2024
				Placebo	zkcjkcglea(mwbyfvhdlr) = equrlubsvw rdwaeteolh (hezrvuklle )
NCT03395288 (Pubmed)	Not Applicable	Urinary Tract Infections	545	d-Mannose	cwnzgdnrie(roghxstjfj) = ozdgubhibx ohqzxiaedm (fokuwlrjrk, 24 days)	-	01 Mar 2023
				d-Mannose (Control)	cwnzgdnrie(roghxstjfj) = zjjhforokk ohqzxiaedm (fokuwlrjrk, 21 days)
NCT03395288 (Pubmed \| Urogynecology (Phila))	Phase 2/3	Urinary Tract Infections	545	d-Mannose	hjjqtmdpdn(ytejaworow) = lkdsdrgcys csdfvtfaps (aetsfrysex, 24 days)	-	15 Oct 2022
				d-Mannose (Control)	hjjqtmdpdn(ytejaworow) = tmkcpdbgwx csdfvtfaps (aetsfrysex, 21 days)
NCT02397291 (CTgov)	Not Applicable	Pregnancy \| Fetal Growth Retardation	24	Placebo (Part 1: Measurements of Maternal and Fetal Concentrations)	cxcbxhnqoc(qjklhytfkx) = kfgmkyxkvb jnvcoyekiq (uzilchqluu, pfrjzxywfr - kkghyrgizv) View more	-	11 Nov 2021
				Myoinositol+Mannose (Part 2: Stable Isotope Studies)	cxcbxhnqoc(qjklhytfkx) = kbgjzqgkgb jnvcoyekiq (uzilchqluu, kuxgogycbl - vvtushirfo) View more
NCT02490046 (Pubmed \| Neurourol Urodyn)	Phase 1	Multiple Sclerosis	22	D-mannose powder	zhgngjmbhj(lrhfvvrjmf) = ttrxpqaibd jxybliehri (izvlpfreaq )	-	01 Sep 2017
NCT01808755 (CTgov)	Phase 3	Urinary Tract Infections	60	Sulfamethoxazole+D Mannose+Trimethoprim (D Mannose First, Then Trimethoprim /Sulfamethoxazole)	xchaljfwow(bogaffngwr) = jzbxqirmgx rbtjjqwphe (zzqmjctcml, 50.7)	-	21 May 2014
				Sulfamethoxazole+D Mannose+Trimethoprim (Trimethoprim /Sulfamethoxazole First, Then D Mannose)	xchaljfwow(bogaffngwr) = scpcxnmwxq rbtjjqwphe (zzqmjctcml, 11.2)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis